Literature DB >> 7378171

FR-31564, a new phosphonic acid antibiotic: bacterial resistance and membrane permeability.

H Kojo, Y Shigi, M Nishida.   

Abstract

Mutants which acquired resistance to FR-31564 were also resistant to fosfomycin and vice versa. Some exceptions to cross-resistance were found among clinical isolates of certain species. FR-31564 was found to be incorporated into bacterial cells more efficiently than fosfomycin although the extent of incorporation varied among species. In particular, the uptake rate of FR-31564 by a strain of Pseudomonas aeruginosa was ten times that of fosfomycin. The uptake rate of FR-31564 by both FR-31564- and fosfomycin-resistant mutants was less than one-tenth of that by the parent strain. FR-31564 was scarcely inactivated in the culture broths of FR-31564-resistant strains. All of the FR-31564-resistant mutants of P. aeruginosa came under the classification of strains lacking an L-alpha-glycerophosphate transport system.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7378171     DOI: 10.7164/antibiotics.33.44

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  13 in total

1.  1-Deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacterial resistance to fosmidomycin.

Authors:  Rakesh K Dhiman; Merrill L Schaeffer; Ann Marie Bailey; Charles A Testa; Hataichanok Scherman; Dean C Crick
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

2.  Comparison of the response of Escherichia coli to fosfomycin and fosmidomycin.

Authors:  Y Kanimoto; D Greenwood
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

3.  Activity of fosmidomycin in an in vitro model of the treatment of bacterial cystitis.

Authors:  Y Kanimoto; D Greenwood
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

4.  Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.

Authors:  Eugene Uh; Emily R Jackson; Géraldine San Jose; Marcus Maddox; Robin E Lee; Richard E Lee; Helena I Boshoff; Cynthia S Dowd
Journal:  Bioorg Med Chem Lett       Date:  2011-10-05       Impact factor: 2.823

5.  Fosfomycin resistance plasmids do not affect fosfomycin transport into Escherichia coli.

Authors:  J León; J M García-Lobo; J M Ortiz
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Pharmacokinetics and metabolism of fosmidomycin, a new phosphonic acid, in rats and dogs.

Authors:  T Tsuchiya; K Ishibashi; M Terakawa; M Nishiyama; N Itoh; H Noguchi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

7.  In vitro and in vivo antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent.

Authors:  H C Neu; T Kamimura
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

8.  Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis.

Authors:  Géraldine San Jose; Emily R Jackson; Amanda Haymond; Chinchu Johny; Rachel L Edwards; Xu Wang; R Carl Brothers; Emma K Edelstein; Audrey R Odom; Helena I Boshoff; Robin D Couch; Cynthia S Dowd
Journal:  ACS Infect Dis       Date:  2016-10-12       Impact factor: 5.084

9.  Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic.

Authors:  T Murakawa; H Sakamoto; S Fukada; T Konishi; M Nishida
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

10.  Synergy of fosmidomycin (FR-31564) and other antimicrobial agents.

Authors:  H C Neu; T Kamimura
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.